16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>

Program

”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.

www.bonescanindex.org

www.exini.com/software-bone-bsi/

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.

________________________________________________________________________

EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,

www.exini.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jun
VWS
Normal 0 false false false DA X-NONE X-NONE ..
41
18 Jun
GEN
GW er en troll, der burdte have begrænset sin adgang til 1 dagligt indlæg.   Formøbleren  
36
21 Jun
BAVA
Men hvis man ikke efterrationalisere mere end, "nå", så er der da gode penge at hente i bankerne, ve..
27
18 Jun
GEN
Øhhh- du må da være hans mor.... Jeg har endnu ikke konstateret at han har ramt noget som helst ......
20
22 Jun
VELO
Må sige at det er ekstremt svært at finde ud af hvad Veloxis har at byde på, og om der er gode mulig..
19
19 Jun
BEO-SDB
God eftermiddag,   Efter at have set på de forskellige meninger og argumenter på FB, EI, Avanza og L..
18
19 Jun
BAVA
Nyhedsflowet fra Bavarian resten af 2017 bliver enormt spændende. Husk at det er Biotek og nyheder i..
17
21 Jun
BAVA
Fra 0,77% til ca. 0,4%.   Derfor faldt den ikke tilbage i går. De har købt ca 120.000 aktier.   Det ..
15
18 Jun
GEN
Vores kære orakel her på EI, Goodwrench, også kaldet GW, er ved at blive et stort fænomen. Hans udta..
15
21 Jun
VWS
Aarhus, Danmark, 2017-06-21 16:17 CEST (GLOBE NEWSWIRE) --     I forbindelse med at OOO Fortum Energ..
14

Alliance Trust PLC : Transaction in Own Shares

14/06/2017 07:00:13
14 June 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 13 June 2017 the Company purchased for cancellation 209,000 ordinary shares of 2.5p each at a price of 708.0748p per share.  Therefore, the total number of voting rights in the Company is now 354,575,762.    The above figure (354,575,762) may be used by shareholder..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

13/06/2017 15:20:46
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Quarterly Update for the Quarter to 30 April 2017

13/06/2017 12:50:10
13 June 2017 ICG Enterprise Trust Plc Quarterly Update For the quarter to 30 April 2017 Highlights Share price Total Return1 of 5.7% for the quarter and 39.9% for the 12 months to 30 April 2017 Net asset value per share Total Return1 of 0.6% for the quarter and 19.9% for the 12 months The Portfolio1 is valued at £54..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
2
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix® (vortioxetine) sNDA
3
Results of Operations for the Year Ended December 31, 2016 - American Overseas Group Limited Announces Net Loss Of $7.5 Million and Operating Loss of $14.6 Million For The Year Ended December 31, 2016
4
NXT Energy Solutions Announces Results of Annual General Meeting
5
Barrick and NOVAGOLD to Advance Ongoing Donlin Gold Project Optimization With Approved $8-Million Drill Program

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 June 2017 21:34:25
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170623.1 - EUROWEB1 - 2017-06-23 22:34:25 - 2017-06-23 21:34:25 - 1000 - Website: OKAY